VR Adviser’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$181K Buy
13,338
+10,069
+308% +$148K 0.01% 34
2026
Q2
$50.7K Buy
+3,269
New +$36.1K ﹤0.01% 33

Other funds holding MTRI

VR Adviser's MTRI Position: Q3 2026 in Review

VR Adviser increased its Mentari Therapeutics, Inc. Common Stock (MTRI) stake by 308% in Q3 2026, buying an estimated $148K and bringing the position to 13,338 shares worth $181K. The position accounts for 0.01% of the portfolio, ranked #34.

VR Adviser first reported a position in MTRI in Q2 2026 and has held it in 2 quarters since. 16 funds tracked by Wall St. Rank hold MTRI as of Q3 2026.

  • VR Adviser held 13,338 shares of Mentari Therapeutics, Inc. Common Stock worth $181K as of Q3 2026.
  • VR Adviser bought 10,069 Mentari Therapeutics, Inc. Common Stock shares in Q3 2026, an estimated $148K.
  • Mentari Therapeutics, Inc. Common Stock made up 0.01% of VR Adviser's portfolio in Q3 2026, its #34 holding.
  • VR Adviser first reported a position in Mentari Therapeutics, Inc. Common Stock in Q2 2026 and has held it in 2 quarters since.
  • 16 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2026.

Based on VR Adviser's 13F filing for Q3 2026, filed 16 Nov 2026.